Welcome to NuclearMediX
Transforming Cancer Care
Revolutionising Cancer Treatment:
Scalable and Accessible Radiopharmaceuticals
for Enhanced Patient Care
About Us
At NuclearMediX, we understand the challenges of providing SSTR-PET tracers for diagnosing neuroendocrine tumours (NETs) and other cancers.
Emerging from Imperial College London’s esteemed Aboagye lab, we specialize in the development and application of radiopharmaceuticals. Our mission is to offer the most accessible and affordable SSTR-PET tracers to transform cancer care.
Our scalable 18F radiotracer platform offers 10x the production volume and 3x the delivery distance, ensuring timely, reliable, and widely available diagnostic solutions.
The Current Problem
The current landscape of cancer diagnosis and treatment for neuroendocrine tumours (NETs) is hindered by a significant shortage (a 50% supply-demand gap) of SSTR-PET tracers.
This shortage causes delays in essential diagnostic imaging, impacting patient management and increasing stress for those awaiting timely scans. Existing solutions often suffer from limited production capacities and short shelf-lives, restricting their availability and accessibility to patients and healthcare providers.
Diagnostic Delays and Patient Stress
The shortage of diagnostic imaging tools causes significant delays in patient care, increasing anxiety for those waiting for essential scans.
Production Limits and Shelf-Life Issues
Many current diagnostic imaging solutions are hampered by limited production capabilities and short shelf-lives, reducing their availability for patients and healthcare providers.
Challenges in Accessibility of Diagnostic Imaging
Limited production and short shelf-lives of imaging solutions create barriers to timely and accessible diagnostic services for patients and healthcare professionals.
Our Solution
NuclearMediX addresses the shortage of SSTR-PET tracers by leveraging our innovative 18F radiotracer platform. Our flagship product, [18F]FET-βAG-TOCA, ensures a consistent and reliable supply of high-quality SSTR-PET diagnostic agents. By utilizing the most prolific medical radionuclide, 18F, our technology enables 10x the production volume and 3x the delivery distance compared to existing solutions.
This significantly expands availability, reduces delays, and ensures that patients receive timely and effective diagnostics. Our solution not only meets the current demand but also provides a scalable and sustainable approach to future-proof SSTR-PET diagnosis globally
Reducing Delays
By significantly increasing availability and reducing delays, our technology ensures patients receive timely and effective diagnostic services.
Enhanced Production
Leveraging the prolific 18F radionuclide, our solution boosts production volume by 10x and extends delivery reach by 3x over existing alternatives.
Reliable Supply
Our flagship product, [18F]FET-βAG-TOCA, guarantees a consistent and reliable supply of superior SSTR-PET diagnostic agents.
Scalable and Sustainable
Our innovative solution not only meets current demands but also offers a scalable and sustainable approach, future-proofing SSTR-PET diagnosis worldwide.
Our Applications
Oncologists
Enhancing cancer care for your patients.
Nuclear Medicine departments
Providing a scalable and sustainable approach to future-proof SSTR-PET diagnosis.
Surveys
Are you an Oncologist?
Provide feedback to help shape your patients future.
Are you a Patient?
Help us gain insight to improve your clinical experience.
Are you in the Nuclear Medicine Dept?
Shape the future of cancer care and share your thoughts now.
Our Founding Team
Dr. Ruisi Fu
Entrepreneurial Lead
Prof. Eric Aboagye
Principal Scientific Advisor
